Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
NCT06303739Phase 3Active, not recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of psilocybin in treatment-resistant depression (TRD) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Hamilton Depression Rating Scale at 2 weeks, Quick Inventory of Depressive Symptomatology Self-Report at 2 weeks and 2 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06303739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06303739.